New Biomarkers Predict Skin Rash Severity in EGFRI Cancer Therapy
A recent study published in Oncotarget has identified specific microRNAs (miRNAs) that could serve as biomarkers for predicting skin rash severity in patients treated with epidermal growth factor receptor inhibitors (EGFRIs). The research, led by Miroslava J. Jarzabek, suggests that miR-21, miR-31, and miR-520e could be used as treatment-dependent markers for EGFRI-induced skin toxicity.
Dr. Julia Carolin Stingl from The University Hospital of the RWTH Aachen explained that EGFRI is used to treat various cancer types, including non-small-lung-cancer, head-and-neck-cancer, colon-rectal-cancer, and pancreas-cancer. Despite the common side effect of skin toxicity, affecting around 70% of patients, the new study provides a better understanding of this condition. The study found that in patients treated with EGFR inhibiting monoclonal antibodies, serum concentrations of miR-21 and miR-520e were negatively correlated with the severity of skin rash, while miR-31 showed a positive correlation. This suggests that these miRNAs could be used as predictive biomarkers for therapy efficacy, as previous studies have shown a correlation between overall survival and the appearance of a skin rash.
The study, titled 'Association between miRNA signatures in serum samples of patients treated with EGFR inhibitors and skin toxicity', can be accessed via the Oncotarget journal and has a DOI of https://doi.org/10.18632/oncotarget.27953. While the study's biggest limitation is the lack of pre-treatment serum samples, the findings offer promising avenues for further research and personalized treatment approaches in cancer patients.
Read also:
- Premios Senior Living Las Arcadias Honours Champions of Elderly Rights
- Rise in Flu Cases: Timing and Reasons Explored by Medical Experts for Flu Vaccination
- Nursing Infants: Advantages, Factors to Ponder, Guidelines, Essential Gear
- Anticipated Increase in Uninsured Residents to Pose Challenge for Local Healthcare Infrastructure
